TAS-203, an oral phosphodiesterase 4 inhibitor, exerts anti-inflammatory activities in a rat airway inflammation model-Reference-Cited by-同舟云学术

TAS-203, an oral phosphodiesterase 4 inhibitor, exerts anti-inflammatory activities in a rat airway inflammation model

Published:2019-04 Issue: Volume:849 Page:22-29
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Demizu Shunsuke,Asaka Naomasa,Kawahara Hiroyuki,Sasaki Eiji

Publisher

Elsevier BV

Subject

Pharmacology

Reference32 articles.

1. Selective inhibition of phosphodiesterase type IV suppresses the chemotactic responsiveness of rat eosinophils in vitro;Alves;Eur. J. Pharmacol.,1996

2. Effects of the new benzimidazole derivative TAS-203, an orally active phosphodiesterase 4 inhibitor, on airway inflammation in rats and emetic responses in ferrets;Asaka;Arzneimittelforschung,2010

3. IL-13-induced changes in the goblet cell density of human bronchial epithelial cell cultures: map kinase and phosphatidylinositol 3-kinase regulation;Atherton;Am. J. Physiol. Lung Cell Mol. Physiol.,2003

4. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use;Bender;Pharmacol. Rev.,2006

5. Roflumilast in symptomatic chronic obstructive pulmonarydisease: two randomised clinical trials;Calverley;Lancet,2009

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. cAMP-PDE signaling in COPD: Review of cellular, molecular and clinical features;Biochemistry and Biophysics Reports;2023-07

2. Phosphodiesterase inhibitors and lung diseases;Advances in Pharmacology;2023

3. The Involvement of PDE4 in the Protective Effects of Melatonin on Cigarette-Smoke-Induced Chronic Obstructive Pulmonary Disease;Molecules;2021-10-30

4. Role of the mucins in pathogenesis of COPD: implications for therapy;Expert Review of Respiratory Medicine;2020-03-19

5. Mucins and Asthma: Are We Headed to the Revolutionary Road?;Journal of Clinical Medicine;2019-11-13